Qlaris Bio Closes $24M Series B Financing - FinSMEs

Qlaris Bio Closes $24M Series B Financing - FinSMEs

6 days from now

Apr 30, 2024  · Qlaris Bio, a Dedham, MA-based clinical-stage biotechnology company, raised $24M in Series B funding.. The round was led by Canaan and New Leaf Venture Partners, …

finsmes.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma Business Wire Tue, Apr 30, 2024, …

yahoo.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Qlaris Bio’s investors include Canaan and New Leaf Venture Partners, both of which were co-lead investors in the company’s $25 million Series A funding round in August …

businesswire.com

Qlaris Bio Completes $24M Series B Financing Round To Advance …

6 days from now

Apr 30, 2024  · Qlaris Bio, Inc. announced that it has closed a $24 million Series B financing round. Co-led by Canaan and New Leaf Venture Partners, the financing also included new …

eyesoneyecare.com

Qlaris Bio Completes $24 Million Series B Financing Round To

6 days from now

Apr 30, 2024  · DEDHAM, Mass.--(BUSINESS WIRE)-- Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today …

biospace.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma. ... today announced that it has closed a $24 …

vcaonline.com

Qlaris Bio Closes $24M Series B Round - Vcnewsdaily.com

6 days from now

Qlaris Bio, a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing …

vcnewsdaily.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it …

qlaris.bio

VM - Qlaris Bio Completes $24 Million Series B Financing Round To ...

6 days from now

May 1, 2024  · DEDHAM, Mass.—Qlaris Bio, Inc., (Qlaris) a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, has announced the close of a $24 …

visionmonday.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures. Qlaris Bio, Inc. …

financialcontent.com

Series B - Qlaris Bio - 2024-04-30 - Crunchbase

6 days from now

Apr 30, 2024  · Venture Capital Access Online — Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for …

crunchbase.com

Qlaris Bio Raises $24M In Financing For IOP-lowering Glaucoma …

6 days from now

May 3, 2024  · Qlaris Bio, Inc. announced it has locked in a total of $24 million during its Series B financing round to support the ongoing clinical development of the company’s intraocular …

eyesoneyecare.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Proceeds from the financing will support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure (IOP) by …

aijourn.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma. By. Life Sciences Times - April …

blstimes.com

Qlaris Bio

6 days from now

Apr 30, 2024  · Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma ... 2024 — Qlaris Bio, Inc. …

qlaris.bio

Qlaris Bio Closes $24 Million Series B Financing - Citybiz

6 days from now

Apr 30, 2024  · DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today …

citybiz.co

Invest In Qlaris Bio Stock | Buy Pre-IPO Shares | EquityZen

6 days from now

May 23, 2024  · Qlaris Bio Closes $24M Series B Financing. finsmes • May 23, 2024. Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP …

equityzen.com

Qlaris Bio Completes $24 Million Series B Financing Round To …

6 days from now

Apr 30, 2024  · Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has

einpresswire.com